Biological characteristics and clinical management of uveal and conjunctival melanoma  

作　　者：SNJEŽANA KAŠTELAN ANA DIDOVIĆPAVIČIĆ DARIA PAŠALIĆ TAMARA NIKUŠEVA-MARTIĆ SAMIRČANOVIĆ PETRA KOVAČEVIĆ SUZANA KONJEVODA 

机构地区：[1]School of Medicine,University of Zagreb,Zagreb,10000,Croatia [2]Department of Ophthalmology,Clinical Hospital Dubrava,Zagreb,10000,Croatia [3]Department of Ophthalmology,Zadar General Hospital,Zadar,23000,Croatia [4]Department of Medical Chemistry,Biochemistry and Clinical Chemistry,School of Medicine,University of Zagreb,Zagreb,10000,Croatia [5]Department of Biology and Genetics,School of Medicine,University of Zagreb,Zagreb,10000,Croatia [6]School of Medicine,University of Split,Split,21000,Croatia [7]Department of Health Studies,University of Zadar,Zadar,23000,Croatia

出　　处：《Oncology Research》2024年第8期1265-1285,共21页肿瘤学研究（英文）

摘　　要：Uveal and conjunctival melanomas are relatively rare tumors;nonetheless,they pose a significant risk of mortality for a large number of affected individuals.The pathogenesis of melanoma at different sites is very similar,however,the prognosis for patients with ocular melanoma remains unfavourable,primarily due to its distinctive genetic profile and tumor microenvironment.Regardless of considerable advances in understanding the genetic characteristics and biological behaviour,the treatment of uveal and conjunctival melanoma remains a formidable challenge.To enhance the prospect of success,collaborative efforts involving medical professionals and researchers in thefields of ocular biology and oncology are essential.Current data show a lack of well-designed randomized clinical trials and limited benefits in current forms of treatment for these tumors.Despite advancements in the development of effective melanoma therapeutic strategies,all current treatments for uveal melanoma(UM)and conjunctival melanoma(CoM)remain unsatisfactory,resulting in a poor long-term prognosis.Ongoing trials offer hope for positive outcomes in advanced and metastatic tumors.A more comprehensive understanding of the genetic and molecular abnormalities involved in the development and progression of ocular melanomas opens the way for the development of personalized therapy,with various potential therapeutic targets currently under consideration.Increased comprehension of the molecular pathogenesis of UM and CoM and their specificities may aid in the development of new and more effective systemic therapeutic agents,with the hope of improving the prognosis for patients with metastatic disease.

关 键 词：Uveal melanoma Conjunctival melanoma Genetic characteristics Immune checkpoint inhibitors Target molecular inhibitors 

分 类 号：R739.5[医药卫生—肿瘤]